Publications by May A El-Antrawy

Publications by authors named "May A El-Antrawy"

J Antibiot (Tokyo)

November 2024

The study focuses on Escherichia coli and Klebsiella pneumoniae, bacteria that often cause infections and are increasingly resistant to common antibiotics, including β-lactams and fluoroquinolones.
It found that 36% of clinical isolates produced extended-spectrum β-lactamases (ESBLs), showing significant resistance, although some were still susceptible to chloramphenicol and doxycycline.
The research also examined the plasmid profiles of quinolone-resistant ESBL producers, revealing a common plasmid across isolates that likely carries resistance genes, with a higher frequency of gene transfer within the same bacterial genus compared to different genera.

J Antibiot (Tokyo)

April 2023

Short chain fatty acids (SCFAs) produced in a healthy gut are shown to have antibacterial properties against intestinal pathogens, making them important for food safety and human health.
This study investigates the in vitro effects of SCFAs on the efficacy of new β-lactam/β-lactamase inhibitor combinations against E. coli strains from gastrointestinal infections, finding that SCFAs can enhance the effectiveness of these antibiotics.
Results indicate that the impact of SCFAs varies with pH and concentration, with higher colonic levels significantly inhibiting E. coli growth and reducing virulence gene expression, suggesting potential for improved treatment strategies using SCFAs alongside antibiotics.

Iran J Microbiol

August 2022

A study was conducted to evaluate the effectiveness of new combinations of β-lactam antibiotics and β-lactamase inhibitors against 140 clinical isolates from infections, revealing a significant resistance problem in traditional treatments.* -
The research found that 46.4% of the isolates produced extended spectrum β-lactamase (ESBL), with high resistance rates to classical combinations like amoxicillin/clavulanate (40.7%) and ampicillin/sulbactam (42.9%).* -
New combinations, particularly ceftazidime/avibactam, showed promising results, making 94.3% of the resistant isolates susceptible, suggesting these novel treatments may restore effectiveness against